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ABSTRACT: Pyrimidines have always received considerable attention because of their
importance in synthesis and elucidation of biochemical roles, in particular that of vitamin
B1. Herein, we describe a reaction pathway in a Grignard reagent-based synthesis of
substituted pyrimidines. A general synthesis of α-keto-2-methyl-4-amino pyrimidines
and their C6-substituted analogues from 4-amino-5-cyano-2-methylpyrimidine is
reported. The presence of the nitrile substituent in the starting material also results in
an unusual reaction pathway leading to C6-substituted 1,2-dihydropyrimidines. Grignard
reagents that give normal pyrimidine products under standard reaction conditions can be
switched to give dihydropyrimidines by holding the reaction at 0 °C before quenching.
■ INTRODUCTION
The synthesis of pyrimidines has always been a priority topic
for investigation because of their widespread use as scaﬀolds in
medicinal, pharmaceutical, and academic chemistries. Recently,
there has been a marked return to prominence of these
structures, particularly in the functionalized amino pyrimidine
series,1 as synthetic targets. Although a majority of these
examples are 2-amino pyrimidines, examples of 4-2 and 6-
aminopyrimidines3 are also notable features. These vital
building blocks of life are found in many biologically signiﬁcant
molecules, including structures like DNA 1, drugs such as
zidovudine 2,4,5 and barbiturate sodium thiopental 3 (Figure
1). Pyrimidines are also investigated for the treatment of the
neurological disorders Beriberi and Korsakoﬀ syndrome and as
a recognition motif for binding in thiamine diphosphate-
dependent enzymes (compound 4, Figure 1).6,7
Because of their versatile hydrogen-bonding interactions,
these small fragments have been intensively investigated by
medicinal chemists during the past decade. Their applications
in GSK’s antimalaria drug trimethoprim 5,8 antibiotic
bacimethrin 6,9 and in the treatments of thiamine deﬁ-
ciency,10−12 are well-documented (Figure 2).
Commonly, the synthesis of pyrimidine rings utilizes a
sodium alkoxide-catalyzed condensation reaction between
urea, an aldehyde, and a malonic ester. Most methodologies
to form these rings utilize this process, now called the Biginelli
reaction.13−15 Assembly of the core aromatic structure permits
further functionalization with a range of reactive groups. The
initial synthetic strategies to access the valuable 4-amino-2-
methyl pyrimidine substitution pattern were originally
developed by Williams16 (Scheme 1). The reported procedure
is outlined below and was subsequently modiﬁed by others for
the development and production scale-up of vitamin B1
synthesis.
Although the 4-amino-2-methyl pyrimidines have been
investigated with many diﬀering structural modiﬁcations,17−19
there are very few examples for the synthesis of α-keto-4-
amino-2-methyl pyrimidines and their analogues.20 As the core
pyrimidine ring is observed widely throughout nature, it was
surprising to ﬁnd such a lack of examples because these α-keto
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Figure 1. (a) DNA fragment, HIV drug zidovudine, sodium
thiopental, and vitamin B1.
Figure 2. Aminopyrimidines in GSK’s trimethoprim and antibiotic
bacimethrin.
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structural analogues could be good candidates for inhibitor
mimics and for potential structural manipulations in structure−
activity relationship studies. To address this issue, we have
devised a new synthetic route, which uses cheap and readily
available starting materials, to construct α-keto-4-amino-2-
methyl pyrimidines.
■ RESULTS AND DISCUSSION
Our approach to α-keto-4-amino-2-methyl pyrimidines is
based on the inclusion of a nitrile substituent at the 5-position
to enable the introduction of a wide variety of R groups. This
allows us to exploit the easy availability of 2-methyl-4-amino-5-
cyano-pyrimidines (Scheme 2).17
Thus, our synthesis of a range of diﬀerently substituted α-
keto-2-methyl-4-amino pyrimidines began by employing the
established condensation reaction of cheap and accessible
reagents, acetamidine hydrochloride 14 and ethoxymethylene-
malonitrile 15, which after recrystallization of the crude
product from ethanol gave the required nitrile 13 in a 78%
yield (Scheme 3, step 1).17
We now turned to a series of preliminary experiments to
assess the optimum temperature for addition of the Grignard
reagent to the nitrile. Addition of the Grignard reagent at 0 °C
and warming to 40 °C gave total consumption of the starting
material after 16 h. Lower temperatures resulted in incomplete
consumption and required longer reaction times. Addition of
the appropriate Grignard reagent produced the desired keto
products 12 with various R groups after simple column
chromatography in yields of 16−68% (see Scheme 4 and Table
1, product type A). The infrared spectra of the products
showed an unusually low position for the CO stretching
vibration of the ketones at about 1650 cm−1. In the 1H nuclear
magnetic resonance (NMR) spectra, the signals for the NH2
protons came at two separate chemical shifts, presumably
because of H-bonding to the adjacent carbonyl oxygen by one
of the protons of the amino substituent. This strong
intramolecular hydrogen bonding also accounts for the unusual
position of the CO stretching vibration for these
compounds and is consistent with the data reported for 1-
(2-aminophenyl)ethanone.21 During the puriﬁcation of our
ketone products, it became apparent that other byproducts had
been formed during the Grignard reaction. Characterization of
these byproducts allowed us to identify some unexpected
structures, which reveal an unusual alternative pathway for the
addition of the Grignard reagent at the C-6 position of the
pyrimidine ring (Scheme 4, product types B and C).
The formation of these unexpected substitution patterns
(see Scheme 4) was apparent from the lack of the C6 aromatic
proton at ∼8.0 ppm in the 1H NMR spectrum and the retained
Scheme 1. Williams’ Synthesis of 4-Amino-2-methyl
Pyrimidine
Scheme 2. Synthetic Approach to Access α-Keto-4-amino-2-
methyl Pyrimidines with a Wide Variety of R Groups
Scheme 3. New Synthesis of the Pyrimidyl Ketones
Scheme 4. Surprising Range of Products Isolated from the
Addition of Grignard Reagents to the Nitrile-Substituted
Aminopyrimidine
Table 1. Product Structures and Yields of Grignard
Addition Products A, B, or C
entry R
temp,
°C
% yield
(type A)
% yield
(type B)
% yield
(type C)
1 Me 0−40a 18 (50%)b
2 Me 40c 17 (85%)
3 Et 0−40a 19 (68%)b 20 (27%)d
4 Et 40c 21 (80%)
5 Pr 0−40a 22 (16%)b 23 (20%)d
6 Pr 0−25e 24 (67%)
7 Pr 40c 22 (22%)
8 Bu 0−40a 25 (18%)d
9 Bu 0−25e 26 (87%)
10 i-Pr 0−25e 27 (56%)
11 t-Bu 40c 28 (42%)
12 phenyl 0−40a 29 (25%)b 30 (40%)d
13 phenyl 0−25e 31 (81%)
14 vinyl 40c 32 (76%)
15 HCC 40c
16 HCC 0−25e
aGrignard reagent was added at 0 °C, and the reaction mixture was
then warmed to 40 °C and then left to cool and stirred at rt overnight.
bBy procedure I. cBy procedure III (Grignard reagent was added at 40
°C). dBy procedure II (like procedure I but neutralized with aqueous
NaHCO3, before extraction).
eBy procedure IV in which the reaction
temperature was maintained at 0 °C for 3 h before being allowed to
warm to rt overnight.
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strong CN stretching vibration at 2100 cm−1 in the infrared
spectrum. After adjusting the reaction conditions, addition of
the methyl and ethyl Grignard reagents at 40 °C instead of 0
°C gave the [1,2]-dihydropyrimidine analogues of type C in
good yields (80−85%). These structures were identiﬁed by the
presence of the methyl signal as a doublet with 3J coupling (6.0
Hz) to the CH proton (q, 3J = 6.0 Hz) located at 4.1 ppm
(e.g., see Figure 3). The assignment of these spectral features
was conﬁrmed by the analysis of 1H correlation spectroscopy
data. The [1,2]-dihydro products also retained the distinctive
nitrile stretch at 2100 cm−1 in their infrared spectra. The key
features discussed above allow the characterization data for the
products of type B/C and the anticipated product of type A to
be easily distinguished. Remarkably, these [1,2]-dihydro
compounds remained stable at room temperature over a
period of weeks, despite the loss of aromaticity following the
addition of the Grignard reagent. Some aryl-22 and ferrocenyl-
substituted23 examples appear to share the same stability
shown by our nitrile-substituted structures, whereas Lyle24 has
reported instability in the cyano-substituted dihydropyridine
analogues.
A plausible mechanism for the synthesis of side products of
types B/C could arise as a consequence of the Schlenk
equilibrium25 between the Grignard reagent RMgX, R2Mg, and
MgX2. Coordination of the Lewis acidic MgX2 to the N1
nitrogen of the pyrimidine to form 16 would make the C6
position more electrophilic and hence promote attack by the
Grignard reagent (Scheme 5). Moreover, an electron-with-
drawing group adjacent to this position would further increase
the electrophilicity of the C6 position providing an explanation
for why, in the 5-cyano series, this side-reaction is far more
favored. An alternative possibility, however, would be a radical
mechanism for the transfer of the R group, followed by loss of
H• by an oxidative step to form 17.
Examples of reactions that are capable of forming stereo-
genic centers from an aromatic system using Grignard reagents
are rare, but a notable precedent for this type of transformation
has been described in the synthesis of antifungal agent
Voriconazole by Pﬁzer.26 The methyl and ethyl C6-substituted
analogues have been reported previously in the synthesis of
vitamin B1 analogues, but were acquired by condensation
chemistry as described by Todd et al.27,28 This condensation
approach has not been applied to the synthesis of other
analogues containing modiﬁcations at this position, so the new
examples described here, which are obtained by the Grignard
approach, will open up a general access to this class of
structures.
Interestingly, the Schlenk equilibrium is often controlled by
changes to the Grignard reagent, solvent, or temperature. To
assess the optimum conditions, a range of temperatures from
(−78 to 40 °C) were tested, but this served only to increase
the consumption of the starting nitrile 13 and did not aﬀect the
product outcome. It was noticeable that addition of the
Grignard at 0 °C followed by warming to 40 °C gave a mixture
of products, so some Grignard additions at 40 °C were
attempted. As the Schlenk equilibrium should favor formation
of the R1MgX species at higher temperatures and in a polar
aprotic solvent, the involvement of Lewis acidic MgX2 could be
reduced, and therefore C-6 addition should be decreased. This,
however, with our initial choice of methyl and ethyl Grignard
reagents, gave 17 and 21 as the sole products (Table 1, entries
2 and 4).
A range of solvents were then examined to assess their aﬀect
upon product distribution. As tetrahydrofuran (THF) had
already been used for the preliminary experiments, we sought
to decrease the solvent polarity. Diethyl ether was tested under
the same conditions, and from the analysis of the 1H NMR
spectra, it was obvious that only methyl ketone and the
unreacted starting material were present. Attempts using 1,4-
dioxane resulted in the precipitation of the MgX2 salts.
Removal of these MgX2 salts by ﬁltration was expected to
improve the selectivity for the formation of the ketone
Figure 3. Structure of racemic 17 with the CHMe feature that gives a characteristic C6 quartet and C7 doublet in the 1H NMR spectrum.
Scheme 5. Proposed Mechanism of the formation of [1,2]-
Dihydropyrimidine 17
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compound; however, this proved not to be the case, and the
under these conditions, the attempted reaction gave only the
recovered unreacted starting material.
On the basis of the mechanism proposed in Scheme 5, it
seemed probable that the products that retained the nitrile
group originated by initial addition of the nucleophile to the
heteroaromatic ring (producing the [1,2]-dihydro product of
type C) and that oxidation under the reaction conditions later
resulted in rearomatization to give 5-cyano-6-alkyl-2-methyl-
pyrimidine products of type B. This hypothesis was tested for
Grignard reagents (R1 = Et, Pr, Bu, and Ph; Table 1 entries 3,
5, 8, and 12) that tended to give low yields and only products
of types A and B. By avoiding the high temperature of 40 °C
and keeping the reaction mixture at 0 °C for 3 h, more time
was allowed for the addition at C6 to go to completion before
the reaction was quenched.
Under these conditions (Table 1, entries 6, 9, 10, and 13),
the [1,2]-dihydro products of type C were isolated at moderate
to good yields. Bulky Grignard reagents (branched R1 groups
such as i-Pr and t-Bu) give poorer results (56 and 42%,
respectively). In the other cases, (R1 = Me, Et, Pr, and Bu), the
yields of the [1,2]-dihydro products ranged from 67 to 87%.
Extending the study to phenyl- and vinylmagnesium bromide,
we were able to show that the low temperature conditions
worked well to improve the yields with phenylmagnesium
bromide, giving [1,2]-dihydro product 31 in an 81% yield
(compare entries 12 and 13), and our original 40 °C reaction
conditions were suitable with vinylmagnesium bromide, giving
32 in a 76% yield.
On the basis of these trends, it appears that the unexpected
formation of [1,2]-dihydropyrimidine is in fact the preferred
addition pathway and proceeds eﬃciently, albeit slowly, at 0
°C. At higher temperatures, the addition at the nitrile begins to
become signiﬁcant, so that reactions that are allowed to warm
up before all of the Grignard reagent has been consumed can
produce substantial amounts of the ketones (type A products).
Type B products in many cases arise by rearomatization of
[1,2]-dihydropyrimidines, accounting for the failure to isolate
type C products in these cases. In other cases, however, the
addition of the Grignard reagent can be performed at 40 °C to
give methyl- and ethyl-substituted [1,2]-dihydropyrimidines in
a high yield. We proposed that this diﬀerence arises from the
diﬀerences in stability of type C products under strong acid
(HCl; entries 1, 3, 5, 8, and 12) conditions used in the quench,
compared to the weak acid (ammonium chloride) used for
entries 2, 4, 6, 7, 9, 10, 11, 13, and 14. Steric bulk in the
nucleophile (e.g., entry 8) seems to block addition at the
nitrile, and type A products were not formed with
butylmagnesium bromide. Alkynyl Grignard reagents are less
reactive and HCCMgBr failed to add to 13, even at 40 °C.
Crystallization and X-ray analysis of the simple methyl
substituted example 17 conﬁrmed the [1,2]-dihydro structure
and the presence of the stereogenic center at C6 (Figure 4).
C6 is displaced 0.078(2) Å from the good mean plane of the
rest of the heterocyclic ring, which supports the presence of
extended π-overlap into the nitrile substituent. The shorter
bond length of C1−C2 [1.379(2) Å] when compared to the
C1−C6 bond of the C−CHMe [1.510(2) Å] suggests the
presence of the alkene π bond in conjugation with the nitrile
substituent within the aromatic π-system.
Measurement of the CN bond length C11−N12 [1.158(2)
Å] indicates a typical length for this group, although the C1−
C11 C−CN [1.402(2) Å] bond length lies between a normal
C−C bond (1.5 Å) and an sp2 CC (1.3 Å), thereby
suggesting the presence of a partial sp2 bond character between
the aromatic π-system and the nitrile bond. At C6, the CHMe
position adopts the classic tetrahedral geometry with a bond
angle for the atom group N5−C6−H6 at 109.0(9)° and the
bond length for C1−C6 at 1.510(2) Å, whereas the shorter
bonds between the sp2 centers of C1−C2 and C4−N3 have
lengths of 1.379(2) and 1.312(2) Å, respectively. Interestingly,
these structures form a hydrogen-bonded dimer pair (racemic,
with R and S conﬁgurations) around a center of symmetry,
forming a binding pattern similar to that observed in DNA
base pairs (Figure 4), which becomes extended through further
pairs of hydrogen bonds (see the Supporting Information).
This paper identiﬁes three competing pathways for the
addition of Grignard reagents to the readily available 4-amino-
2-methyl-5-cyanopyrimidine starting material, giving access to
either the sought after α-keto-4-amino-2-methyl pyrimidines or
alternative products arising from substitution of the pyrimidine
ring itself. Especially in the cases where the exclusive formation
of a single product has been identiﬁed, the results presented
here should open the way for the exploitation of these
substitution patterns in future research. Furthermore, studies
are now in progress to extend the range of examples that give
exclusively the unusual chiral 1,2-dihydropyrimidines to
introduce alternative reactive functional groups at the C6
position (e.g., alkynes) to prepare the way for the development
of an enantioselective version of the procedure.
Ideally, this research would facilitate a wider range of
ongoing synthetic modiﬁcations such as Diels−Alder cyclo-
addition chemistry and metal-catalyzed cross-coupling reac-
tions, which could utilize the vinyl adduct 32. Each in their
own way, the intended α-keto products and the unusual ring-
substituted products are ideal structures to access a wide range
of pyrimidine-derived compounds that will be of value in
medicinal and bioorganic chemistry. Our procedure avoids the
need for extensive puriﬁcation steps and so provides a potential
“gateway compound” suited for easy functionalization in future
studies. It also oﬀers potential access to key intermediates in
the substantial quantities needed for sustained biochemical/
pharmaceutical research projects and scale-up processes.29
Furthermore, the ketones made available in this way would be
suitable prochiral candidates for reductions to provide useful
Figure 4. diagram for the crystal structure of 4-amino-2-methyl-5-
cyano-6-methyl-[1,2]-dihydropyrimid-ine 17. Thermal ellipsoids are
drawn at the 50% probability level.
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intermediates for the chiral synthetic pool and/or enzymatic
studies.30,31
■ EXPERIMENTAL SECTION
General Considerations. All reactions were carried out in
dry solvents, unless otherwise stated. Anhydrous THF, diethyl
ether, and toluene were distilled over sodium following
literature methods. All solvents and chemicals were purchased
from appropriate suppliers including Sigma-Aldrich, Acros,
TCI, Fluorochem, Alfa Aesar, and Fisher. Infrared spectra were
obtained on a PerkinElmer spectrum 100 Fourier transform
infrared spectrometer, with most compounds dissolved in
dichloromethane and measured as a ﬁlm on a NaCl disc. In
cases where compounds were not soluble in this solvent, the
infrared spectrum was obtained using an attenuation total
reﬂection plate. 1H and 13C NMR spectra were obtained using
a Bruker (Ascend) 500 MHz spectrometer and a sample
express autosampler. Mass spectra were measured by the
EPSRC UK National Mass Spectrometry Facility, Swansea, UK
using an LTQ Orbitrap XL spectrometer. Melting points were
recorded on a BUCHI melting point apparatus B545. X-ray
diﬀraction data were recorded at the UEA on an Oxford
Diﬀraction Xcalibur-3/Sapphire3 CCD diﬀractometer. The
data were then processed with the CrysAlisPro-CCD and
-RED programs.32,33 The structure was determined by the
direct method routines in the SHELXS program34 and reﬁned
by full-matrix least-squares methods on F2’s in SHELXL34
using WinGX.35 Scattering factors for neutral atoms were taken
from the International Tables for X-ray Crystallography.36
Preparation of 4-Amino-5-cyano-2-methylpyrimidine
(13).17 Sodium (0.19 g) was added in small pieces to ethanol
(4.0 mL) to produce a 2 M solution of sodium ethoxide. Then,
acetamide hydrochloride (0.80 g, 8.50 mmol) was added.
Filtration through celite gave a clear solution, which upon
addition of ethoxymethylene malonitrile (0.50 g, 4.10 mmol)
produced a yellow precipitate that was collected by ﬁltration
and recrystallized from ethanol to give the title compound as
ﬁne yellow needles (1.10 g, 70%). mp 245−247 °C [lit.17 mp
246−248 °C]. 1H NMR (500 MHz, DMSO-d6): δ 8.52 (s,
1H), 7.77 (s, 2H), 2.40 (s, 3H) ppm. 13C NMR (126 MHz,
DMSO-d6): δ 170.6, 162.8, 161.6, 116.2, 87.1, 26.4 ppm. IR
νmax: 3378, 3334 (NH2), 2223 (sp CN), 1672, 1584, 1542 (C−
H, sp2 stretch) cm−1.
Preparation of tert-Butylmagnesium Bromide. 2-Methyl-
2-bromopropane (1.0 mL, 8.9 mmol, 1 equiv) in dry THF (9.0
mL) was added dropwise to a predried round-bottom ﬂask
containing magnesium turnings (427 mg, 17.8 mmol, 2.0
equiv) in anhydrous THF (20 mL). After activation with a
small amount of iodine, addition was maintained to keep a
gentle reﬂux. The reaction was then stirred at room
temperature (rt) for 3 h. The Grignard reagent was titrated
against 1,10-phenanthroline and isopropyl alcohol.
Typical Procedure I for the Synthesis of α-Keto-4-
amino-2-methylpyrimidines (Products of Type A). 5-(4-
Amino-2-methylpyrimidinyl)propan-1-one (19). To 4-amino-
5-cyano-2-methylpyrimidine 13 (200 mg, 1.5 mmol) in THF
(5 mL) was added ethylmagnesium bromide in THF (3 M, 5.3
mmol, 1.74 mL, 3.5 equiv) dropwise at 0 °C. The reaction
mixture was warmed to 40 °C and left to stir overnight. The
reaction was then quenched with 1 M HCl (10 mL), stirred for
a further 24 h, and then extracted with EtOAc (3 × 10 mL).
The combined organic layers were washed with brine (10 mL),
dried over MgSO4, ﬁltered, and evaporated under pressure to
leave a ﬁne powder. Column chromatography on silica eluting
with EtOAc/hexanes (1:3 v/v) gave the product as a white
solid (168 mg 68%). Rf = 0.6 EtOAc/hexanes 1:3 v/v. mp
160−162 °C. 1H NMR (500 MHz, CDCl3): δ 8.73 (s, 1H),
8.62 (s, 1H), 5.67 (s, 2H), 2.87 (q, 3J = 7.3 Hz, 2H, H-4), 2.47
(s, 3H, H-1), 1.15 (t, 3J = 7.3 Hz, 3H, H-5) ppm. 13C NMR
(126 MHz, CDCl3): δ 201.4, 171.1, 161.9, 158.9, 109.2, 29.5,
26.4, 8.1 ppm. IR νmax: 3385, 3263, 3109, 2980 (sp
3 C−H
stretch), 1657, 1625, 1528 (sp2 C−H stretch) cm−1. HRMS
(ESI-LTQ Orbitrap XL) m/z: [M + H]+ calcd for C8H12N3O,
166.0975; found, 166.0972.
Typical Procedure II for the Synthesis of 4-Amino-5-
cyano-2-alkyl- or 2-Arylpyrimidines (Products of Type
B). 4-Amino-5-cyano-2-methyl-6-phenylpyrimidine (30).32
To 4-amino-5-cyano-2-methylpyrimidine 13 (200 mg, 1.5
mmol) in THF (5 mL) was added phenylmagnesium bromide
in THF (3 M, 5.2 mmol, 1.74 mL, 3.5 equiv) dropwise at 0 °C.
The reaction was warmed to 40 °C and left to stir overnight,
then quenched with 1 M HCl (10 mL), and stirred for a
further 24 h. The reaction was then neutralized with aqueous
NaHCO3 and extracted with EtOAc (3 × 10 mL). The
combined organic layers were washed with brine (10 mL),
dried over MgSO4, ﬁltered, and evaporated under reduced
pressure to leave a ﬁne powder. Column chromatography on
silica eluting with EtOAc/hexanes (gradient, 5:1 v/v to pure
EtOAc) gave the product as a white powder (315 mg, 40%). Rf
= 0.2 EtOAc/hexanes 5:1. v/v. 1H NMR (500 MHz, DMSO-
d6): δ 7.87−7.82 (m, 2H), 7.63−7.51 (m, 3H), 2.47 (s, 3H)
ppm (this compound would only dissolve in DMSO-d6; signals
for the NH2 protons were not observed because of exchange
with H2O in the solvent).
13C NMR (126 MHz, DMSO-d6): δ
169.7, 168.4, 164.7, 136.8, 131.3, 129.4, 129.0, 116.7, 84.2,
26.4 ppm. IR νmax: 3379, 3330 (NH2), 2168 (sp CN), 1680,
1626, 1561 cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M +
H]+ calcd for C12H11N4, 211.0978; found, 211.0978.
Typical Procedure III for the Synthesis of 4-Amino-5-
cyano-2-methyl-6-alkyl- or 6-Alkenyl-[1,2]-dihydropyr-
imidines at 40 °C (Products of Type C). 4-Amino-5-
cyano-2-methyl-6-vinyl-[1,2]-dihydropyrimidine (32). To 4-
amino-5-cyano-2-methylpyrimidine 13 (2.5 g, 19 mmol, 1
equiv) in THF (50 mL) was added vinylmagnesium bromide
in THF (3 M, 65 mmol, 21.8 mL, 3.5 equiv) dropwise at 40
°C. The reaction mixture was left to stir overnight and then
quenched with saturated aqueous ammonium chloride (20
mL) at 0 °C and stirred for further 48 h and extracted with
EtOAc (3 × 10 mL). The combined organic layers were
washed with brine (10 mL), dried over MgSO4, ﬁltered, and
evaporated under reduced pressure to give the product as a ﬁne
yellow powder (2.24 g, 76%). mp 171−173 °C. 1H NMR (500
MHz, DMSO-d6): δ 8.47 (br s, 1H), 5.88 (s, 2H), 5.76 (ddd,
3J = 16.9, 9.9, 6.9 Hz, 1H), 5.07−5.00 (m, 2H), 4.49 (d, 3J =
6.9 Hz, 1H), 1.88 (s, 3H) ppm. 13C NMR (126 MHz, DMSO-
d6): δ 160.8, 159.4, 139.9, 122.1, 114.3, 52.5, 51.4, 21.8 ppm.
IR νmax: 3316, 3302 (NH2), 2171 (sp CN), 1734 (sp
2 CO),
1683, 1638, 1601 (sp2 C−H stretch) cm−1. HRMS (ESI-LTQ
Orbitrap XL) m/z: [M + H]+ calcd for C8H11N4, 163.0978;
found, 163.0975.
Typical Procedure IV for the Synthesis of 4-Amino-5-
cyano-2-methyl-6-alkyl- or 6-Alkenyl-[1,2]-dihydropyr-
im-idines from 0 °C to rt (Products of Type C). 4-Amino-
5-cyano-2-methyl-6-propyl-[1,2]-dihydropyrimidine (24). To
4-amino-5-cyano-2-methylpyrimidine 13 (200 mg, 1.5 mmol)
in anhydrous THF (5 mL) at 0 °C was added propylmagne-
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sium chloride (2 M, 5.2 mmol, 2.6 mL, 3.5 equiv) dropwise at
0 °C. The reaction mixture was stirred at 0 °C for 3 h and then
left to warm to rt overnight. The reaction mixture was cooled
to 0 °C and quenched with saturated aqueous ammonium
chloride (10 mL) and left to stand for 3 h. The product was
extracted with EtOAc (3 × 10 mL), washed with brine (10
mL), dried over MgSO4, ﬁltered, and evaporated to dryness to
give the title compound as a ﬁne yellow powder (180 mg,
67%). mp 163−165 °C. 1H NMR (400 MHz, DMSO-d6): δ
8.21 (s, 1H), 5.74 (s, 2H), 4.04 (dd, J = 18.8, 4.6 Hz, 1H), 1.84
(s, 3H), 1.46−1.23 (m, 4H), 0.92−0.88 (m, 3H) ppm. 13C
NMR (101 MHz, DMSO-d6): δ 161.4, 160.1, 122.6, 51.7, 49.3,
41.4, 22.2, 16.9, 14.2 ppm. IR νmax: 3310, 3252 (NH2), 2100
(CN), 1650, 1617, 1538 (sp2 C−H stretch) cm−1. HRMS
(ESI-LTQ Orbitrap XL) m/z: [M + H]+ calcd for C9H15N4,
179.1291; found, 179.1291.
Synthesis of α-Keto-4-amino-2-methylpyrimidines. 5-
(4-Amino-2-methylpyrimidinyl)ethanone (18). Following
procedure I, using methylmagnesium bromide followed by
column chromatography on silica eluting with ethyl acetate/
hexanes (1:3 v/v) gave the title compound as a white solid
(470 mg, 50%). mp 170−172 °C. 1H NMR (500 MHz,
CDCl3): δ 8.70 (s, 1H), 8.57 (s, 1H), 5.72 (s, 1H), 2.50 (s,
3H), 2.48 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ
198.2, 171.4, 161.8, 159.8, 109.8, 26.6, 26.1 ppm. IR νmax:
3372, 3114, 1651 (sp2 CO), 1590, 1520 (sp2 C−H aromatic
stretch) cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M + H]+
calcd for C7H10N3O, 152.0818; found, 152.0815.
5-(4-Amino-2-methylpyrimidinyl)butan-1-one (22). Fol-
lowing procedure I, using n-propylmagnesium bromide
followed by column chromatography on silica eluting with
EtOAc/hexanes (2:1 v/v) gave the title compound as a white
solid (43 mg, 16%). Rf = 0.3 EtOAc/hexanes 2:1 v/v. mp
147−149 °C. 1H NMR (500 MHz, CDCl3): δ 8.73 (s, 1H),
2.81 (t, 3J = 7.4 Hz, 3H), 2.50 (s, 3H), 1.73−1.64 (m, 2H, H-
5), 0.94 (t, 3J = 7.4 Hz, 3H, H-6) ppm. 13C NMR (126 MHz,
CDCl3): δ 200.6, 170.5, 162.0, 158.2, 109.3, 40.3, 25.8, 17.9,
13.8 ppm. IR νmax: 3373, 3265 (NH2) 1653, 1629, 1534 (sp
2
C−H stretch) cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M
+ H]+ calcd for C9H14N3O, 180.1131; found, 180.1129.
This product was also obtained following procedure III;
using n-propylmagnesium bromide followed by column
chromatography on silica eluting with EtOAc/hexanes (2:1
v/v) gave the title compound as a white solid (60 mg, 22%).
5-(4-Amino-2-methylpyrimidinyl)phenone (29). Following
procedure I, using phenylmagnesium bromide followed by
column chromatography on silica eluting with EtOAc/hexanes
(gradient, 5:1 v/v to pure EtOAc) gave the title compound as a
white powder (200 mg, 25%), Rf = 0.5 EtOAc/hexanes 5:1 v/
v. mp 182−184 °C. 1H NMR (500 MHz, DMSO-d6): δ 8.33
(s, 1H), 8.12 (s, 2H), 7.68−7.63 (m, 3H), 7.61−7.54 (m, 2H),
2.45 (s, 3H) ppm. 13C NMR (126 MHz, DMSO-d6): δ 196.2,
170.63, 162.8, 161.8, 138.6, 132.5, 129.4, 129.0, 108.9, 26.3
ppm. IR νmax: 3381, 2925, 1627, 1577, 1598 (sp
2 C−H stretch)
cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M + H]+ calcd
for C12H12N3O, 214.0975; found, 214.0973.
Synthesis of 4-Amino-5-cyano-2-alkyl- or 2-Arylpyr-
imidines. 4-Amino-5-cyano-6-ethyl-2-methylpyrimidine
(20).27 Following procedure II, using methylmagnesium
bromide followed by column chromatography on silica eluting
with EtOAc/hexanes (gradient, 1:1 v/v to pure EtOAc) gave
the title compound as a white powder (66 mg, 27%). Rf = 0.7
EtOAc/hexanes 1:1 v/v. mp 197−199 °C [lit.27 mp 193−194
°C]. 1H NMR (500 MHz, CDCl3): δ 5.42 (s, 2H), 2.66 (q,
3J
= 7.6 Hz, 2H), 2.38 (s, 3H), 1.16 (t, 3J = 7.6 Hz, 3H) ppm. 13C
NMR (126 MHz, CDCl3): δ 175.5, 170.4, 163.3, 115.3, 86.3,
30.6, 26.4, 12.8 ppm. IR νmax: 3377, 3340 (NH2), 2223 (CN),
1682, 1553, 1577 (sp2 C−H stretch) cm−1. HRMS (ESI-LTQ
Orbitrap XL) m/z: [M + H]+ calcd for C8H11N4, 163.0978;
found, 163.0974.
4-Amino-5-cyano-2-methyl-6-propylpyrimidine (23). Fol-
lowing procedure II, using n-propylmagnesium bromide
followed by column chromatography on silica eluting with
EtOAc/hexanes (2:1 v/v) gave the title compound as a
yellow/white powder (53 mg, 20%). Rf = 0.6 EtOAc/hexanes
2:1 v/v. mp 176−177 °C. 1H NMR (500 MHz, CDCl3): δ
5.50 (s, 2H), 2.71 (t, 3J = 10 Hz, 2H), 2.47 (s, 3H), 1.75−1.66
(m, 2H), 0.94 (t, 3J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz,
CDCl3): δ 173.0, 169.1, 162.1, 114.1, 85.6, 37.5, 25.1, 21.2,
12.4 ppm. IR νmax: 3368, 3338 (NH2) 1653, 1629, 224 (CN),
1678, 1553, 1417 (sp2 C−H stretch) cm−1. HRMS (ESI-LTQ
Orbitrap XL) m/z: [M + H]+ calcd for C9H13N4, 177.1135;
found, 177.1133.
4-Amino-6-butyl-5-cyano-2-methylpyrimidine (25). Fol-
lowing procedure II, using n-butylmagnesium bromide
followed by column chromatography on silica eluting with
EtOAc/hexanes (gradient, 1:1 v/v to pure EtOAc) gave the
title compound as a white solid (50 mg, 18%). Rf = 0.6
EtOAc/hexanes 1:1 v/v. mp 180−182 °C. 1H NMR (500
MHz, CDCl3): δ 5.69 (s, 2H), 2.72 (t,
3J = 10 Hz, 2H), 2.46
(s, 3H), 1.68−1.60 (m, 2H), 1.40−1.31 (m, 2H), 0.88 (t, 3J =
7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 175.2,
170.4, 163.6, 116.0, 87.1, 37.0, 31.6, 26.8, 23.1, 14.2 ppm. IR
νmax: 3339, 3379, 2227 (sp CN), 1687, 1559, 1461 (sp
2 C−H
stretch) cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M + H]+
calcd for C10H15N4, 191.1291; found, 191.1289.
Synthesis of 4-Amino-5-cyano-2-methyl-6-alkyl- or
-6-Phenyl- or 6-Alkenyl-[1,2]-dihydropyrimdines. 4-
Amino-5-cyano-2,6-dimethyl-[1,2]-dihydropyrimidine (17).
Following procedure III, using methylmagnesium bromide
gave the title compound as a ﬁne yellow powder (2.4 g, 85%).
mp 221−222 °C. 1H NMR (500 MHz, DMSO-d6): δ 8.27 (s,
1H), 5.77 (s, 2H), 4.17 (q, 3J = 6.0 Hz, 1H), 1.84 (s, 3H), 1.18
(d, 3J = 6.0 Hz, 3H) ppm. 13C NMR (126 MHz, DMSO-d6): δ
161.0, 159.7, 122.4, 53.6, 45.5, 25.5, 22.1 ppm. IR νmax: 3399,
3304, 2152 (sp CN), 1658, 1608, 1563 (sp2 C−H stretch)
cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M + H]+ calcd
for C7H11N4, 151.0978; found, 151.0975.
4-Amino-5-cyano-6-ethyl-2-methyl-[1,2]-dihydropyrimi-
dine (21). Following procedure III, using ethylmagnesium
bromide gave the title compound as a ﬁne yellow powder (2.1
g, 80%). mp 213−215 °C. 1H NMR (500 MHz, DMSO-d6): δ
8.19 (s, 1H, H-6), 5.75 (s, 2H, H-2), 4.09 (td, 3J = 4.6, 2.3 Hz,
1H), 1.86 (s, 3H), 1.50−1.38 (m, 2H), 0.86 (t, 3J = 7.4 Hz,
3H) ppm. 13C NMR (126 MHz, DMSO-d6): δ 161.5, 160.3,
122.7, 51.0, 50.6, 31.2, 21.7, 8.1 ppm. IR νmax: 3372, 3326
(NH2), 2180, 2149 (sp CN), 1659, 1600, 1565 (sp
2 C−H
stretch) cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M + H]+
calcd for C8H13N4, 165.1135; found, 165.1135.
4-Amino-6-butyl-5-cyano-2-methyl-[1,2]-dihydropyrimi-
dine (26). Following procedure IV, using n-butylmagnesium
bromide gave the title compound as a ﬁne yellow powder (250
mg, 87%). 1H NMR (500 MHz, DMSO-d6): δ 8.22 (s, 1H),
5.74 (s, 2H), 4.08 (td, J = 4.8, 2.4 Hz, 1H), 1.86 (s, 3H),
1.45−1.40 (m, 2H), 1.34−1.25 (m, 4H), 0.90 (t, J = 6.9 Hz,
3H) ppm. 13C NMR (126 MHz, DMSO): δ 161.1, 160.2,
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122.3, 51.3, 49.6, 38.4, 25.4, 22.8, 21.9, 14.5 ppm. IR νmax:
2159 (sp CN), 1631, 1588, 1520 cm−1. HRMS (ESI-LTQ
Orbitrap XL) m/z: [M + H]+ calcd for C10H17N4, 193.1448;
found, 193.1447.
4-Amino-5-cyano-2-methyl-6-iso-propyl-[1,2]-dihydro-
pyrimidine (27). Following procedure IV, using iso-propyl-
magnesium bromide gave the title compound as a ﬁne yellow
powder (150 mg, 56%) mp 170−171 °C. 1H NMR (400 MHz,
DMSO-d6): δ 8.14 (s, 1H), 5.75 (s, 2H), 3.89 (d, J = 2.6 Hz,
1H), 1.87 (s, 3H), 1.57 (s, 1H), 0.86 (d, 3H), 0.82 (d, 3H)
ppm. 13C NMR (101 MHz, DMSO-d6): δ 162.1, 160.8, 123.0,
55.4, 49.9, 36.7, 21.7, 17.3, 16.4 ppm. IR νmax: 3368, 3321
(NH2), 2175 (CN), 1652, 1601, 1565 (sp
2 C−H stretch)
cm−1. HRMS (ESI-LTQ Orbitrap XL) m/z: [M + H]+ calcd
for C9H15N4, 179.1291; found, 179.1290.
4-Amino-5-cyano-2-methyl-6-tert-butyl-[1,2]-dihydropyri-
midine (28). Following procedure III, using tert-butylmagne-
sium bromide gave the title compound as a ﬁne yellow powder
(120 mg, 42%). mp 217−219 °C. 1H NMR (500 MHz,
DMSO-d6): δ 8.38 (s, 1H), 5.82 (s, 2H), 3.61 (s, 1H), 1.96 (s,
3H), 0.85 (s, 9H) ppm. 13C NMR (126 MHz, DMSO-d6): δ
161.9, 161.6, 124.2, 58.9, 48.9, 40.8, 25.0, 21.9 ppm. IR νmax:
2159 (sp CN), 1637, 1598, 1562 cm−1. HRMS (ESI-LTQ
Orbitrap XL) m/z: [M + H]+ calcd for C10H17N4, 193.1448;
found, 193.1445.
4-Amino-5-cyano-2-methyl-6-phenyl-[1,2]-dihydropyri-
midine (31). Following procedure IV, using phenylmagnesium
bromide gave the title compound as a ﬁne yellow powder (256
mg, 81%). 1H NMR (400 MHz, DMSO-d6): δ 8.79 (br s, 1H),
7.4−7.37 (m, 2H), 7.31−7.27 (m, 3H), 5.91 (s, 2H), 5.11 (s,
1H), 1.92 (s, 3H) ppm. 13C NMR (101 MHz, DMSO-d6): δ
145.9, 129.4, 129.0, 128.2, 127.9, 127.2, 127.0, 122.4, 53.8,
22.1. IR νmax: 3345, 3317 (NH2), 2123 (CN), 1646, 1601,
1550 (sp2 C−H stretch) cm−1 HRMS (ESI-LTQ Orbitrap XL)
m/z: [M + H]+ calcd for C12H13N4, 213.1135; found,
213.1137.
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